EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma

Kazuchika Nishitsuji iD, Remi Mito, Midori Ikezaki, Hiromu Yano iD, Yukio Fujiwara iD, Eri Matsubara iD, Taro Nishikawa, Yoshito Ihara iD, Kenji Uchimura, Naoyuki Iwahashi, Takuro Sakagami, Makoto Suzuki und 1 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Kazuchika Nishitsuji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Lung Neoplasms, Carcinoma, Squamous Cell, Transcriptome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Wakayama Medical University, Mochida Memorial Foundation for Medical and Pharmaceutical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor suppressor TP53 gene, the most frequently mutated gene in human cancers, produces the product tumor protein p53, which plays an essential role in DNA damage. p53 protein mutations may contribute to tumorigenesis by loss of tumor suppressive functions and malignancy of cancer cells via gain‐of‐oncogenic functions. We previously reported that mutant p53 proteins form aggregates and that cytoplasmic p53 aggregates were associated with poor prognosis in human ovarian cancer. However, the prognostic impact of p53 aggregation in other tumors including lung squamous cell carcinoma (SCC) is poorly understood. Here, we demonstrated that lung SCC cases with cytoplasmic p53 aggregates had a significantly poor clinical prognosis. Analysis via patient‐derived tumor organoids (PDOs) established from lung SCC patients and possessing cytoplasmic p53 aggregates showed that eliminating cytoplasmic p53 aggregates suppressed cell proliferation. RNA sequencing and transcriptome analysis of p53 aggregate‐harboring PDOs indicated multiple candidate pathways involved in p53 aggregate oncogenic functions. With lung SCC‐derived cell lines, we found that cytoplasmic p53 aggregates contributed to cisplatin resistance. This study thus shows that p53 aggregates are a predictor of poor prognosis in lung SCC and suggests that detecting p53 aggregates via p53 conventional immunohistochemical analysis may aid patient selection for platinum‐based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Lung NeoplasmsCarcinoma, Squamous CellTranscriptomeCisplatinHumansPrognosisCell Line, TumorCytoplasmFemaleDrug Resistance, NeoplasmCell ProliferationMutationGene Expression Regulation, NeoplasticMale

Stichwörter der Autor:innen

RNA sequencingcisplatinlung squamous cell carcinomap53p53 aggregate

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanCisplatin

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine, Wakayama Medical University, Wakayama, Japan.
  • Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576 CNRS, Université de Lille, Villeneuve d'Ascq, France.
  • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Thoracic and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, Wakayama, Japan.

ORCID-Profile: Kazuchika Nishitsuji, Hiromu Yano, Yukio Fujiwara, Eri Matsubara, Yoshito Ihara, Yoshihiro Komohara

Förderung

  • Japan Society for the Promotion of Science
  • Wakayama Medical University
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Suzuken Memorial Foundation
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Nishitsuji, K., Mito, R., Ikezaki, M., Yano, H., Fujiwara, Y., Matsubara, E., Nishikawa, T., Ihara, Y., Uchimura, K., Iwahashi, N., Sakagami, T., Suzuki, M., & Komohara, Y. (2024). Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma. Cancer Science. https://doi.org/10.1111/cas.16252

Vancouver

Nishitsuji K, Mito R, Ikezaki M, Yano H, Fujiwara Y, Matsubara E, et al. Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma. Cancer Science. 2024. doi:10.1111/cas.16252

BibTeX
@article{Nishitsuji2024,
  author = {Nishitsuji, Kazuchika and Mito, Remi and Ikezaki, Midori and Yano, Hiromu and Fujiwara, Yukio and Matsubara, Eri and Nishikawa, Taro and Ihara, Yoshito and Uchimura, Kenji and Iwahashi, Naoyuki and Sakagami, Takuro and Suzuki, Makoto and Komohara, Yoshihiro},
  title = {Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16252}
}
Kostenlos starten →